Previous 10 | Next 10 |
home / stock / srpt / srpt articles
Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the consen...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said HubSpot, Inc. (NYSE: HUBS) is like a "mini-Salesforce, it’s got...
Richard Barry, Director at Sarepta Therapeutics (NASDAQ:SRPT), reported a large insider buy on November 6, according to a new SEC filing. What Hap...
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securitie...
Catalent Inc (NYSE: CTLT) shares are trading lower due to its significant exposure to Sarepta Therapeutics Inc (NASDAQ: SRPT) on the...
Sarepta Therapeutics Inc's (NASDAQ: SRPT) EMBARK Phase 3 study of Elevidys in ambulatory boys (those who can walk) with Duchenne muscular ...
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian...
U.S. stocks traded lower this morning, following the release of economic reports. Following the market opening Tuesday, the Dow traded down 0.25% t...
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 38.8% to $0.1250 in pre-market trading. LumiraDX shares fell 25% on Monday after the company ...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...